Psilocybin

Category: other

Pharmacological Mechanism

5-HT2A partial agonist; dephosphorylated to psilocin in vivo.

Half-Life (t½)

PO: 2.5h

Dosing Guidelines

• PO: Typical 3 (Range: 1–30)

Target Organ Systems

• nervous

Interactions

• LSD (caution): Cross-tolerance.

Notes

Schedule I in most jurisdictions. Track for research only.

Pathways It Modulates

• 5-HT2A psychedelic signaling (activator) — 5-HT2A agonist (via psilocin)
• Alzheimer disease (activator) — TrkB + 5-HT2A (synaptogenesis trials in AD-related depression + cognitive decline)
• BDNF / TrkB neurotrophic signaling (activator) — TrkB direct + 5-HT2A (psychoplastogen)
• Kynurenine pathway (inhibitor) — reduces depressive-state IDO activity (post-acute)
• Metabotropic glutamate receptors (activator) — 5-HT2A → cortical glutamate → mGluR cross-talk (downstream)
• Serotonin receptor pharmacology (activator) — 5-HT2A (psilocin is the active metabolite)

Chemical Identifiers

• PubChem CID: 10624
• Formula: C12H17N2O4P
• Molecular weight: 284.25 g/mol
• InChIKey: QVDSEJDULKLHCG-UHFFFAOYSA-N
• SMILES: CN(C)CCC1=CNC2=C1C(=CC=C2)OP(=O)(O)O

References

• PMID 31082098
• PMID 40284409